Wasat Mansoor

Oxford Rd
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Controversies in upper gastrointestinal cancers: adoptive cell therapies.

Controversies in upper gastrointestinal cancers: adoptive cell therapies.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocol.

Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocol.

Journal: Clinical and experimental medicine

Published: December 15, 2025

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.

Journal: ESMO open

Published: July 25, 2025

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.

Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.

Journal: BMJ open

Published: February 06, 2025

Best-Practice Biomarker Testing of Oesophago-Gastric Cancer in the UK: Expert Consensus Recommendations Developed Using a Modified Delphi.

Best-Practice Biomarker Testing of Oesophago-Gastric Cancer in the UK: Expert Consensus Recommendations Developed Using a Modified Delphi.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: June 17, 2024

Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index.

Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 13, 2024

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 09, 2024

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.

Journal: ESMO open

Published: December 20, 2023

Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.

Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.

Journal: The oncologist

Published: October 16, 2023

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.

Journal: Journal for immunotherapy of cancer

Published: May 31, 2023

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.

Journal: EClinicalMedicine

Published: March 27, 2023

Showing 1-12 of 73

Last Updated: 09/26/2026